| 摘要 |
<p>The invention relates to a method for assessing the effect of the integrin inhibitors and small molecule ATP site directed multi kinase inhibitors DI-17E6 (abituzumab), cilengitide, sutinib and sorafenib on angiogenesis associated diseases by the use of certain identified biomarkers. The invention further relates to the use of these drugs for optimizing and scheduling the efficacy of the therapy.</p> |
